A comprehensive analysis of NKG2D ligand expression in CLL and other leukemias has shown that soluble NKG2D ligands in patient sera reduce NKG2D expression on NK cells, resulting in impaired NK antileukemic activity, which depends on the levels of surface-expressed NKG2D ligands [119]. The gene discussed is KLRK1; the disease is leukemia.